Sullivan & Cromwell led all law firm advisers in announced global deals in the first half of 2026, according to Bloomberg. The Firm advised on global announced deals totaling more than $671 billion, representing a 23.7 percent market share.
S&C ranked first in:
- Global announced deals ($671 billion)
- Global private equity deals ($449 billion)
- U.S. announced deals ($632 billion)
- U.S. private equity deals ($449 billion)
- APAC private equity announced deals ($375 billion)
Clients regularly turn to S&C for big-ticket M&A—the average value of S&C’s announced deals in the first half of 2026 was $7.4 billion. S&C advised:
- xAI on its historic $250 billion acquisition by SpaceX;
- Organon on its pending $11.75 billion acquisition by Sun Pharma;
- Merck KGaA on its pending $11.3 billion acquisition of Bio-Techne;
- Masimo on its $9.9 billion acquisition by Danaher; and
- ProLogium on its pending $3.8 billion business combination with Translational Development Corp.